Dataset v2026-08-31 59 providers tracked 72% of prices verified within 7 days Every price carries a source, a date and a grade. How we verify

The cheapest way to get semaglutide

Ranked by published figure, labeled by gate. The cheapest number and the number you can actually get are usually two different routes.

As of August 31, 2026:

Ranked by the dollar figure each route publishes — which is not the same as ranked by what you will pay — the routes to semaglutide in August 2026 are: compounded semaglutide telehealth (verified from $88 per month month-to-month, or $139 true month-to-month); NovoCare self-pay ($349 per month for pens, verified; oral from $149). A commercial plan that covers Wegovy sits outside this ranking on purpose: Novo Nordisk publishes savings offers for covered patients, but no figure is recorded here because none would be true for a given reader — coverage and copays are plan-specific. A route’s published figure is a starting point, not a quote.

Cheapest verified plan$88/mo, Sunlight
Cheapest true month-to-month$139/mo, NexLife
Verified providers ranked12
Same price at every dose8 of 12

The routes, in order of the figure each one publishes

The order below is the published dollar figure, lowest first — and the first thing to know is that the figures are not like-for-like: the cheapest routes are gated by insurance or eligibility and carried here as reported, not verified. The verified routes are the ones this site exists to rank.

1. Compounded semaglutide telehealth

Verified from $88/mo on a plan; $139/mo month-to-month. The verified market: 12 first-party-verified providers, month-to-month range $88–$299 (median $178). Commitment rates and month-to-month rates are different purchases. Rankings: cheapest compounded semaglutide. Compounded semaglutide is not an FDA-approved product.

2. Brand-name Wegovy, self-pay via NovoCare

Verified $349/mo pens; $199 initial fills for qualifying new patients. Modeled year about $4,038. Oral form priced by dose. Detail: Wegovy self-pay price.

3. Commercial insurance that covers Wegovy + manufacturer savings offers

Unranked — no figure recorded here. Novo Nordisk publishes savings offers for commercially insured patients; we have not recorded them first-party and quote no number, because none would be true for a given reader. Coverage and copays are plan-specific.

Definitions used on this page

True month-to-monthA recurring plan requiring no multi-month commitment, priced at the maintenance dose with every mandatory recurring fee included.
All-in priceMedication plus all mandatory recurring fees (membership, provider care where billed separately) and mandatory shipping.
Grade APublic price and terms verified on the provider's own page by our editors.
Grade DThird-party report only; not yet recorded from the provider's own page. Never counted as verified.
Reported figureA price or program term carried from a sponsor or dated third-party account without a first-party check by our editors. Reported figures are always labeled, are never counted in verified statistics, and follow the same discipline as grade-D rows.

Questions this page answers

What is the cheapest way to get semaglutide?

Ranked by the dollar figure each route publishes — which is not the same as ranked by what you will pay — the routes to semaglutide in August 2026 are: compounded semaglutide telehealth (verified from $88 per month month-to-month, or $139 true month-to-month); NovoCare self-pay ($349 per month for pens, verified; oral from $149). A commercial plan that covers Wegovy sits outside this ranking on purpose: Novo Nordisk publishes savings offers for covered patients, but no figure is recorded here because none would be true for a given reader — coverage and copays are plan-specific. A route’s published figure is a starting point, not a quote.

Why are the insurance and Medicare figures labeled “reported”?

Because our verification standard is a first-party check of a purchasable published price, and copay programs are gated by coverage and eligibility that we cannot verify for any given reader. They are carried like grade-D rows: named, attributed, never counted as verified.